The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …

Neuropsychiatric adverse events (NPAEs) observed with the integrase strand transfer
inhibitor (INSTI) dolutegravir (DTG) are usually mild to moderate. The most prevalent …

The era of the integrase strand transfer inhibitors (INSTI s) for the treatment of human
immunodeficiency virus (HIV) infection began with raltegravir in 2007. Since that time …

Abstract Bictegravir, cabotegravir, dolutegravir, elvitegravir, and raltegravir are members of
the latest class of antiretrovirals available to treat human immunodeficiency virus (HIV) …

Background There are conflicting data regarding baseline determinants of virological
nonsuppression outcomes in persons with human immunodeficiency virus (HIV) starting …

Integrase strand transfer inhibitors (INSTIs) have improved the treatment of human
immunodeficiency virus (HIV). There are currently four approved for use in treatment-naïve …

We assessed whether low CD4 count and high viral load (VL) affect the response to
currently preferred ART. We performed a systematic review of randomized, controlled …

BACKGROUND: There are conflicting data regarding baseline determinants of virological
non-suppression outcomes in persons with HIV who initiate antiretroviral treatment (ART) …

Since HIV was identified as the etiological agent of AIDS, there have been significant
advances in antiretroviral therapy (ART) that has reduced morbidity/mortality. Still, the viral …

Integrase strand transfer inhibitors (INSTIs) are a newer class of antiretroviral treatment for
HIV-infected patient. INSTIs currently available for use are raltegravir, elvitegravir …